Menu
Back to User profile » Dr Michael A Ueberall
Papers published by Dr Michael A Ueberall:
Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
Ueberall MA, Essner U, Vila Silván C, Mueller-Schwefe GHH
Journal of Pain Research 2022, 15:267-286
Published Date: 2 February 2022
A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
Überall MA
Journal of Pain Research 2020, 13:399-410
Published Date: 14 February 2020
Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry
Ueberall MA, Essner U, Mueller-Schwefe GHH
Journal of Pain Research 2019, 12:1577-1604
Published Date: 20 May 2019
Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations
Ueberall MA, Mueller-Schwefe GHH
Journal of Pain Research 2016, 9:1001-1020
Published Date: 11 November 2016
Efficacy, tolerability, and safety of an oral enzyme combination vs diclofenac in osteoarthritis of the knee: results of an individual patient-level pooled reanalysis of data from six randomized controlled trials
Ueberall MA, Mueller-Schwefe GH, Wigand R, Essner U
Journal of Pain Research 2016, 9:941-961
Published Date: 4 November 2016
Efficacy, safety, and tolerability of fentanyl pectin nasal spray in patients with breakthrough cancer pain
Ueberall MA, Lorenzl S, Lux EA, Voltz R, Perelman M
Journal of Pain Research 2016, 9:571-585
Published Date: 17 August 2016
Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
Ueberall MA, Eberhardt A, Mueller-Schwefe GHH
International Journal of General Medicine 2016, 9:39-51
Published Date: 24 February 2016
Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids [Corrigendum]
Ueberall MA, Mueller-Schwefe GHH
Journal of Pain Research 2015, 8:807-808
Published Date: 12 November 2015
Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids
Ueberall MA, Mueller-Schwefe GHH
Journal of Pain Research 2015, 8:459-475
Published Date: 10 August 2015